Our data suggest that therapeutic strategies targeting IL6 trans-signaling, IGFBP2, IGFL2, and the coagulation cascade may be efficacious in both SSc-PF and IPF. The gene discussed is IGFBP2; the disease is idiopathic pulmonary fibrosis.